Number: P2C MC0845 Principal Investigator: Picus, Joel
Title: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid, or Islet Cell Cancer
Phase: II Disease Site: Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

This study is being done to learn what effects (good and bad) the combination of temsirolimus and bevacizumab has on you and your cancer. The combination of these two drugs is currently being tested in patients with kidney cancer through another study. Although preliminary results from this study are
encouraging, it is unclear whether this type of treatment will have any benefit in your type of cancer.
Bevacizumab is a drug approved by the Food and Drug Administration (FDA) for use in lung, breast, and colorectal cancer in combination with chemotherapy. Temsirolimus is a drug approved by the FDA for use in some types of kidney cancer. The combination of bevacizumab and temsirolimus is investigational and has
not yet been approved for treatment of any cancer outside of a clinical trial.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)